Evaluation of Plasma Xanthine Oxidoreductase (XOR) Activity in Patients with Cardiopulmonary Arrest
-
- Shibata Yusaku
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Shirakabe Akihiro
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Okazaki Hirotake
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Matsushita Masato
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Shigihara Shota
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Nishigoori Suguru
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Sawatani Tomofumi
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Kiuchi Kazutaka
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Takahashi Masahito
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Murase Takayo
- Department of Radioisotope and Chemical Analysis Center, Sanwa Kagaku Kenkyusho Co., Ltd
-
- Nakamura Takashi
- Department Pharmacological Study Group, Pharmaceutical Research Laboratories, Sanwa Kagaku Kenkyusho Co., Ltd
-
- Kobayashi Nobuaki
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
-
- Asai Kuniya
- Division of Intensive Care Unit, Nippon Medical School Chiba Hokusoh Hospital
この論文をさがす
説明
<p>Plasma xanthine oxidoreductase (XOR) activity in patients with cardiopulmonary arrest (CPA) has not yet been studied.</p><p>A total of 1,158 patients who required intensive care and 231 control patients who attended a cardiovascular outpatient clinic were prospectively analyzed. Blood samples were collected within 15 minutes of admission from patients in intensive care patients, which were divided into a CPA group (n = 1,053) and a no-CPA group (n = 105). Plasma XOR activity was compared between the 3 groups and factors independently associated with extremely elevated XOR activity were identified using a multivariate logistic regression model. Plasma XOR activity in the CPA group (median, 1,030.0 pmol/hour/mL; range, 233.0-4,240.0 pmol/hour/mL) was significantly higher than in the no-CPA group (median, 60.2 pmol/hour/mL; range, 22.5-205.0 pmol/hour/mL) and control group (median, 45.2 pmol/hour/mL; range, 19.3-98.8 pmol/hour/mL). The regression model showed that out-of-hospital cardiac arrest (OHCA) (yes, odds ratio [OR]: 2.548; 95% confidence interval [CI]: 1.098-5.914; P = 0.029) and lactate levels (per 1.0 mmol/L increase, OR: 1.127; 95% CI: 1.031-1.232; P = 0.009) were independently associated with high plasma XOR activity (≥ 1,000 pmol/hour/mL). Kaplan-Meier curve analysis indicated that the prognosis, including all-cause death within 30 days, was significantly poorer in high-XOR patients (XOR ≥ 6,670 pmol/hour/mL) than in the other patients.</p><p>Plasma XOR activity was extremely high in patients with CPA, especially in OHCA. This would be associated with a high lactate value and expected to eventually lead to adverse outcome in patients with CPA.</p>
収録刊行物
-
- International Heart Journal
-
International Heart Journal 64 (2), 237-245, 2023-03-31
一般社団法人 インターナショナル・ハート・ジャーナル刊行会